Workflow
德生物分析师会议-20250612
Dong Jian Yan Bao·2025-06-12 15:23

Group 1: Research Basic Information - The research object is Mingde Bio, belonging to the medical device industry, and the reception time is June 12, 2025. The listed company's reception staff includes the chairman and general manager Chen Lili, independent director Quan Yi, board secretary, financial officer and deputy general manager Wang Rui, and Lin Shangyan, the sponsor representative of Guojin Securities Co., Ltd. [16] Group 2: Detailed Research Institutions - The reception objects are investors who participated online in the "2025 Hubei Listed Companies Investor Online Collective Reception Day Activity and 2024 Annual Performance Briefing", and the type is others [17] Group 3: Core Views - In product development, the company will base itself on competitive areas such as pathogen diagnosis, cardiovascular and cerebrovascular disease diagnosis, and infectious disease diagnosis, enrich and optimize technology platforms and product pipelines, and enhance medical informatization and third - party medical inspection service capabilities. In external investment, it has jointly established a venture capital management company with Junlian Capital and will continue to cooperate with excellent investment institutions to establish industrial funds for external development [22] - The company disclosed the "2025 Valuation Enhancement Plan" in April 2025, aiming to enhance investment value and shareholder return through measures such as improving operating efficiency, seeking investment and mergers, cash dividends, long - term incentive plans, and optimizing information disclosure and investor relations management [23] - Currently, the company has not entered the vaccine or innovative drug fields of the infectious disease industry chain. It is exploring new growth points by increasing R & D investment in in - vitro diagnostic reagents and high - end medical equipment and evaluating investment and merger opportunities [24] - The company will continue to focus on its main business in the in - vitro diagnosis field, explore new business areas such as health food, and pay attention to accounts receivable collection, with the accounts receivable balance decreasing [25] - In March 2025, the company completed the share repurchase plan that started in 2024. If there are subsequent plans, it will go through review and disclosure procedures [25] - The six - item respiratory virus nucleic acid detection kit was put on the market in May 2025, and the current sales proportion is small [26]